Experimental vaccine fights sarcoma with Patient's own immune cells
NCT ID NCT07648069
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a personalized cancer vaccine (SarcVac) combined with immune-boosting drugs and, in some patients, specially grown immune cells. The goal is to see if this approach is safe and can shrink tumors in 16 adults with advanced bone or soft tissue sarcoma who have not responded to standard treatments. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized tumor neoantigen vaccine (SarcVac) with or without tumor-specific lymphocytes and an anti-PD-1 antibody
What this could lead to
If successful, this could point toward a new treatment option for advanced sarcoma patients who have run out of standard therapies.
What could go wrong
This is a very early phase 1 trial with only 16 participants, so it is primarily testing safety. The vaccine may not shrink tumors or improve survival, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••